An early online publication in a new journal – The Lancet Diabetes & Endocrinology – shows research into the risk of dementia in patients with Type 2 diabetes. This is important as patients with diabetes are twice as likely to develop dementia as those without diabetes and it is possible that better treatment can lead to related cost offsets and QoL improvements.
Based on a patient cohort of around 30,000 patients within the Kaiser Permanente Northern California (KPNC) Diabetes Registry, the work found that microvascular disease, diabetic foot, cerebrovascular disease, cardiovascular disease, acute metabolic events, depression, age and education were strongly predictive of dementia.
HEDS has a Type 2 diabetes model – briefly described here - that we have used in several evaluations and we are currently examining how this new work can be incorporated in order to capture these potential benefits of new treatments.
